WO2002022573A3 - Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies - Google Patents

Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies Download PDF

Info

Publication number
WO2002022573A3
WO2002022573A3 PCT/US2001/029165 US0129165W WO0222573A3 WO 2002022573 A3 WO2002022573 A3 WO 2002022573A3 US 0129165 W US0129165 W US 0129165W WO 0222573 A3 WO0222573 A3 WO 0222573A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen peroxide
antibodies
methods
superoxide production
compositions relating
Prior art date
Application number
PCT/US2001/029165
Other languages
French (fr)
Other versions
WO2002022573A2 (en
Inventor
Paul Wentworth
Anita D Wentworth
Lyn H Jones
Kim D Janda
Richard A Lerner
Original Assignee
Scripps Research Inst
Paul Wentworth
Anita D Wentworth
Lyn H Jones
Kim D Janda
Richard A Lerner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Paul Wentworth, Anita D Wentworth, Lyn H Jones, Kim D Janda, Richard A Lerner filed Critical Scripps Research Inst
Priority to EP01981317A priority Critical patent/EP1367998A4/en
Priority to US10/380,905 priority patent/US20040116350A1/en
Priority to AU2002212970A priority patent/AU2002212970B2/en
Priority to AU1297002A priority patent/AU1297002A/en
Priority to JP2002526826A priority patent/JP2005524601A/en
Priority to CA002422586A priority patent/CA2422586A1/en
Publication of WO2002022573A2 publication Critical patent/WO2002022573A2/en
Publication of WO2002022573A3 publication Critical patent/WO2002022573A3/en
Priority to US10/714,567 priority patent/US20040157280A1/en
Priority to US10/714,580 priority patent/US20050129680A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Abstract

The invention relates generally to the field of immunology. More specifically, the invention relates the finding that antibodies can generate superoxide and hydrogen peroxide from singlet oxygen. Accordingly, methods and compositions able to increase or decrease oxidative stress are provided. Also provided are screening assays to identify agents that modulate the ability of a antibody to generate superoxide and hydrogen peroxide. Such agents can be used therapeutically to treat patients in need. Further, the invention provides methods to use antibodies in immunoassays.
PCT/US2001/029165 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies WO2002022573A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP01981317A EP1367998A4 (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US10/380,905 US20040116350A1 (en) 2001-09-17 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
AU2002212970A AU2002212970B2 (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
AU1297002A AU1297002A (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide productionby antibodies
JP2002526826A JP2005524601A (en) 2000-09-15 2001-09-17 Methods and compositions for the production of hydrogen peroxide and superoxide by antibodies
CA002422586A CA2422586A1 (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US10/714,567 US20040157280A1 (en) 2001-09-17 2003-11-14 Antibody mediated ozone generation
US10/714,580 US20050129680A1 (en) 2001-09-17 2003-11-14 Antimicrobial activity of antibodies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23270200P 2000-09-15 2000-09-15
US60/232,702 2000-09-15
US23547500P 2000-09-26 2000-09-26
US60/235,475 2000-09-26
US31590601P 2001-08-29 2001-08-29
US60/315,906 2001-08-29

Publications (2)

Publication Number Publication Date
WO2002022573A2 WO2002022573A2 (en) 2002-03-21
WO2002022573A3 true WO2002022573A3 (en) 2003-10-02

Family

ID=27398334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029165 WO2002022573A2 (en) 2000-09-15 2001-09-17 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies

Country Status (5)

Country Link
EP (1) EP1367998A4 (en)
JP (1) JP2005524601A (en)
AU (2) AU2002212970B2 (en)
CA (1) CA2422586A1 (en)
WO (1) WO2002022573A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419657B2 (en) 2001-08-22 2008-09-02 Cambridge Theranostics Ltd. Treatment of atherosclerotic disorders
CN1738898A (en) * 2002-11-14 2006-02-22 诺瓦提斯公司 Antimicrobial activity of antibodies producing reactive oxygen species
DE10258239A1 (en) * 2002-12-13 2004-06-24 Degussa Ag Formulation used for treating non-chronic alcoholic intoxication, contains alpha-lipoic acid for scavenging free radicals and activating alcohol metabolizing enzymes
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
JP4615470B2 (en) * 2006-03-29 2011-01-19 卓郎 簑和田 Disease treatment and prevention methods and medicines using cerebral cognition
JPWO2008087803A1 (en) * 2007-01-16 2010-05-06 国立大学法人北海道大学 Liposome preparation for iontophoresis encapsulating antioxidant components
BR112015022484A2 (en) * 2013-03-13 2017-07-18 Genentech Inc reduced oxidation formulations
AR095398A1 (en) 2013-03-13 2015-10-14 Genentech Inc FORMULATIONS WITH REDUCED OXIDATION
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
JP6269946B2 (en) * 2014-03-25 2018-01-31 国立大学法人名古屋大学 Bacterial growth inhibition
KR101774636B1 (en) * 2015-04-06 2017-09-04 한국생명공학연구원 Method for Label-free antibody detection basd on nano probe
AU2018375151A1 (en) * 2017-11-29 2020-06-11 Figene, Llc Interaction of fibroblasts and immune cells for activation and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US5362492A (en) * 1990-12-04 1994-11-08 Gruenenthal Gmbh Method of inhibiting multiple organ failure in trauma patients by administration of superoxide dismutase
US5472691A (en) * 1985-09-03 1995-12-05 Symbicom Aktiebolag Superoxide dismutase
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656866B1 (en) * 1990-01-10 1992-05-15 Cis Bio Int PORPHYRIN DERIVATIVES AND METALLOPORPHYRINS POTENTIALLY COUPLED TO A BIOLOGICALLY ACTIVE MOLECULE, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DE4407047A1 (en) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
SE9604581D0 (en) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US5472691A (en) * 1985-09-03 1995-12-05 Symbicom Aktiebolag Superoxide dismutase
US5362492A (en) * 1990-12-04 1994-11-08 Gruenenthal Gmbh Method of inhibiting multiple organ failure in trauma patients by administration of superoxide dismutase
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1367998A4 *

Also Published As

Publication number Publication date
EP1367998A2 (en) 2003-12-10
CA2422586A1 (en) 2002-03-21
AU1297002A (en) 2002-03-26
WO2002022573A2 (en) 2002-03-21
AU2002212970B2 (en) 2007-05-31
EP1367998A4 (en) 2004-03-17
JP2005524601A (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2002022573A3 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
IS2170B (en) Cyclopentanoindole, preparations containing such compounds and treatment methods
SI1492869T1 (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
MA30153B1 (en) ANTI-OX40L ANTIBODIES AND CORRESPONDING METHODS
YU9404A (en) Peptide-based multimeric targeted contrast agents
FI964681A0 (en) Lactobacillus strains of human origin, their compositions and their uses
WO2002078766A3 (en) Combination therapy
DE60237162D1 (en) LIPOSOMENIC LOADING WITH METALLIONS
MXPA04003796A (en) Substituted thioacetamides.
AU2002358667A1 (en) Scented polymer capsules and the production thereof
MX9804588A (en) Use of halogen bleach-comprising compositions for improved mildness to the skin.
DE60120712D1 (en) Kallikrein gen
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
WO2002079474A3 (en) Human b7 polypeptides
ATE397019T1 (en) PREPARATION OF F(AB')2 FRAGMENTS IN MAMMAL CELLS
WO2003031585A3 (en) Transmembrane serine protease 25
TR200402030T4 (en) Substituted I-aminobutan-3-ol-derivatives
DK1204659T3 (en) Serotonergic benzofurans
ATE383874T1 (en) PERYLENEQUINONES FOR USE AS SONOSENSITIZERS
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
MXPA04004090A (en) Substituted 1h-quinolin-2-one compounds.
EP1436279A4 (en) Chemical compounds
AU2002235773A1 (en) Yeast strain for testing the geno- and cytotoxicity of complex environmental contamination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002526826

Country of ref document: JP

Ref document number: 2422586

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001981317

Country of ref document: EP

Ref document number: 2002212970

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001981317

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10380905

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002212970

Country of ref document: AU